©2022 Stanford Medicine
An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed
Not Recruiting
Trial ID: NCT00497770
Purpose
This large, non-randomized observational study is being conducted to provide data about the
impact of ethnic origin on outcomes and resource utilization during the 2nd line treatment of
non-small cell lung cancer (NSCLC) in a routine medical care setting.
Official Title
Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study
Stanford Investigator(s)
Heather Wakelee
Professor of Medicine (Oncology)
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine
Eligibility
Inclusion Criteria:
- Non-small cell lung cancer (NSCLC) (any histologic type)
- Stage IIIB or IV disease
- Should have had 1 line of chemotherapy for Metastatic disease
- Adequate hematologic, hepatic and renal function
- Measurable or evaluable disease
Exclusion Criteria:
- Pregnant or lactating females
Intervention(s):
drug: Pemetrexed
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Cancer Clinical Trials Office
650-498-7061